Last updated on February 2018

Efficacy and Safety of Pregabalin Sustained Release Tablet for Postherpetic Neuralgia


Brief description of study

The purpose of this study is to evaluate the Efficacy and safety of pregabalin sustained release tablet versus placebo for postherpetic neuralgia.

Detailed Study Description

This is a randomized, double-blind, multicenter, placebo-controlled trial to compare the efficacy and safety of pregabalin SR vs placebo in patients with PHN.

The study is conducting at 27 study centers in China. Patients were randomized to receive pregabalin, starting at 165 mg/day and increasing to a maintenance dose of 330 or 660 mg/day, or placebo.

The study includes a 1-week, single-blind, placebo run-in period; a 2-week dose-escalation/optimization phase; a 12-week, fixed-dose treatment period; and a 1-week taper phase.

Clinical Study Identifier: NCT02868801

Contact Investigators or Research Sites near you

Start Over

Liang Yunsheng, M.D.

Fujian Medical University Union Hospital
Fuzhou, China
  Connect »